821392
Last Update Posted: 2009-01-13
Recruiting has ended
All Genders accepted | 18 Years-85 Years |
181 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase III Trial of Febuxostat in Korea Gout Patients
This study was designed to evalute the efficacy and safety of Febuxostat after oral administration to patientd with gout in Korea
This is a multi-center, randomized, double-blind, allopurinol and placebo controlled, parallel, 5 arms, dose response, bridging study of 4 weeks duration.
If subjects pass the screening evaluation after submitting a signed informed consent, they will be randomly assigned to one of the five treatment regimens; febuxostat 40mg, 80mg, 120mg, placebo or allopurinol 300mg. Colchicine 0.6mg QDis given to minimize the risk of gout flares during the washout/run-in period and during the double study period.
Eligibility
Relevant conditions:
Gout
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov